$211 Million is the total value of Prosight Management, LP's 41 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 125.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRTA | Buy | PROTHENA CORP PLC | $21,670,549 | +9.0% | 447,092 | +35.5% | 10.27% | -5.3% |
| MIRM | Buy | MIRUM PHARMACEUTICALS INC | $13,639,181 | +126.5% | 567,826 | +83.9% | 6.47% | +96.9% |
| HUM | Buy | HUMANA INC | $11,651,040 | +31.8% | 24,000 | +39.1% | 5.52% | +14.6% |
| CNC | New | CENTENE CORP DEL | $10,202,347 | – | 161,404 | +100.0% | 4.84% | – |
| KZR | Buy | KEZAR LIFE SCIENCES INC | $10,016,000 | -18.9% | 3,200,000 | +82.4% | 4.75% | -29.5% |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $8,962,105 | +568.8% | 1,074,593 | +820.6% | 4.25% | +481.3% |
| ORIC | Buy | ORIC PHARMACEUTICALS INC | $8,806,500 | +26.7% | 1,545,000 | +30.9% | 4.18% | +10.2% |
| NBIX | New | NEUROCRINE BIOSCIENCES INC | $8,097,600 | – | 80,000 | +100.0% | 3.84% | – |
| ADCT | Buy | ADC THERAPEUTICS SA | $6,351,852 | +257.0% | 3,257,360 | +603.1% | 3.01% | +210.4% |
| ARCT | New | ARCTURUS THERAPEUTICS HLDGS | $6,112,350 | – | 255,000 | +100.0% | 2.90% | – |
| ABCL | Buy | ABCELLERA BIOLOGICS INC | $5,681,601 | +73.8% | 753,528 | +133.5% | 2.69% | +51.0% |
| UNH | Buy | UNITEDHEALTH GROUP INC | $5,167,772 | +94.9% | 10,935 | +118.7% | 2.45% | +69.4% |
| OPCH | Buy | OPTION CARE HEALTH INC | $4,921,173 | +5.6% | 154,900 | +0.0% | 2.33% | -8.2% |
| JNJ | New | JOHNSON & JOHNSON | $3,907,550 | – | 25,210 | +100.0% | 1.85% | – |
| NARI | New | INARI MED INC | $3,832,881 | – | 62,081 | +100.0% | 1.82% | – |
| PCRX | New | PACIRA BIOSCIENCES INC | $3,718,730 | – | 91,123 | +100.0% | 1.76% | – |
| LBPH | New | LONGBOARD PHARMACEUTICALS IN | $3,611,406 | – | 900,600 | +100.0% | 1.71% | – |
| New | ERASCA INC | $3,549,061 | – | 1,179,090 | +100.0% | 1.68% | – | |
| CMPX | New | COMPASS THERAPEUTICS INC | $2,218,041 | – | 678,300 | +100.0% | 1.05% | – |
| MODV | New | MODIVCARE INC | $1,299,204 | – | 15,452 | +100.0% | 0.62% | – |
| TDOC | New | TELADOC HEALTH INC | $1,188,810 | – | 45,900 | +100.0% | 0.56% | – |
| New | KEZAR LIFE SCIENCES INCcall | $626,000 | – | 200,000 | +100.0% | 0.30% | – | |
| INSM | New | INSMED INC | $449,421 | – | 26,359 | +100.0% | 0.21% | – |
| New | 2SEVENTY BIO INC | $433,877 | – | 42,537 | +100.0% | 0.21% | – | |
| AZYO | Buy | AZIYO BIOLOGICS INC | $296,629 | -62.3% | 196,443 | +6.2% | 0.14% | -67.1% |
| Buy | THE ONCOLOGY INSTITUTE INC | $191,101 | -58.0% | 281,902 | +2.3% | 0.09% | -63.3% | |
| XBI | New | SPDR SER TRs&p biotech | $20,805 | – | 273 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.